Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-12 5:06 pm Unchanged | 2026-02-18 | 13D | Q32 Bio Inc. QTTB | ORBIMED ADVISORS LLC | 2,252,987 15.400% | 0 (Unchanged) | Filing History |
| 2026-02-20 8:13 pm Purchase | 2026-02-19 | 13G | Q32 Bio Inc. QTTB | Opaleye Management Inc. | 1,256,228 8.650% | 1,256,228 (New Position) | Filing History |
| 2026-02-19 4:59 pm Purchase | 2026-02-17 | 13G | Q32 Bio Inc. QTTB | Point72 Asset Management, L.P. | 2,057,308 9.900% | 2,057,308 (New Position) | Filing History |
| 2026-02-13 5:08 pm Purchase | 2024-12-31 | 13G | Q32 Bio Inc. QTTB | PFIZER INC PFE | 277,777 2.300% | 277,777 (New Position) | Filing History |
| 2025-04-08 3:14 pm Sale | 2025-03-31 | 13G | Q32 Bio Inc. QTTB | Sio Capital Management LLC | 0 0.000% | -697,413 (Position Closed) | Filing History |
| 2025-02-14 4:10 pm Sale | 2024-12-31 | 13G | Q32 Bio Inc. QTTB | BRISTOL MYERS SQUIBB CO BMY | 200,244 1.640% | -558,901 (-73.62%) | Filing History |
| 2025-02-10 12:57 pm Purchase | 2024-12-31 | 13G | Q32 Bio Inc. QTTB | Sio Capital Management LLC | 697,413 5.730% | 697,413 (New Position) | Filing History |
| 2024-11-14 5:46 pm Unchanged | 2024-09-30 | 13G | Q32 Bio Inc. QTTB | 5AM Ventures IV L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-11-13 4:05 pm Purchase | 2024-03-25 | 13G | Q32 Bio Inc. QTTB | BRISTOL MYERS SQUIBB CO BMY | 759,145 6.230% | 759,145 (New Position) | Filing History |
| 2024-10-25 06:06 am Purchase | 2024-09-30 | 13G | Q32 Bio Inc. QTTB | Temasek Holdings (Private) Ltd | 313,943 2.600% | 313,943 (New Position) | Filing History |
| 2024-05-13 5:34 pm Unchanged | 2024-03-25 | 13G | Q32 Bio Inc. QTTB | ARCH Venture Fund VIII L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-04-04 8:33 pm Purchase | 2024-03-25 | 13D | Q32 Bio Inc. QTTB | ACORN BIOVENTURES, L.P. | 803,425 6.700% | 803,425 (New Position) | Filing History |
| 2024-04-01 9:52 pm Purchase | 2024-03-25 | 13D | Q32 Bio Inc. QTTB | Atlas Venture Fund X L.P. | 864,261 7.200% | 864,261 (New Position) | Filing History |
| 2024-03-29 4:30 pm Purchase | 2024-03-25 | 13G | Q32 Bio Inc. QTTB | Carlyle Group Inc. CG | 1,102,741 9.200% | 1,102,741 (New Position) | Filing History |
| 2024-03-28 4:28 pm Purchase | 2024-03-26 | 13D | Q32 Bio Inc. QTTB | ORBIMED ADVISORS LLC | 2,252,987 18.900% | 2,252,987 (New Position) | Filing History |
| 2024-03-14 07:42 am Purchase | 2024-03-04 | 13G | Homology Medicines, Inc. FIXX | ADAR1 Partners LP | 173,379 5.400% | 173,379 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Homology Medicines, Inc. FIXX | BlackRock Inc. BLK | 92,038 2.900% | -107,283 (-53.82%) | Filing History |
| 2022-02-14 06:28 am Purchase | 2021-12-31 | 13G | Homology Medicines, Inc. FIXX | Temasek Holdings (Private) Ltd | 313,944 9.900% | 135,039 (+75.48%) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Homology Medicines, Inc. FIXX | BlackRock Inc. BLK | 199,321 6.300% | 45,813 (+29.84%) | Filing History |
| 2021-05-06 1:47 pm Sale | 2021-04-30 | 13G | Homology Medicines, Inc. FIXX | JPMORGAN CHASE & CO JPM | 65,859 2.000% | -125,347 (-65.56%) | Filing History |